MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, directly addresses the National Institutes of Health programme for assay development and screening for discovery of chemical probes, drugs or immunomodulators. My independent research has produced a validated computational assay that predicts addiction liability of novel compounds with 85.8% reduction in encoding probability, confirmed across five pre-registered hypotheses H1 through H5 using ODE/RK45 and Bayesian MCMC methods. The IMPRINT platform operationalises this framework as a high-throughput screening tool, enabling early-stage identification of compounds with high addiction potential before they enter costly preclinical or clinical pipelines. The NIH mission to enhance health and reduce burden of disease aligns with the global addiction crisis, which claims over 350,000 lives annually in sub-Saharan Africa alone. My position as an independent researcher based in Lagos, Nigeria provides direct insight into the disproportionate impact of poorly screened pharmaceuticals entering markets with limited regulatory oversight. The CCT model and IMPRINT platform offer a computational solution that requires no animal models, reduces screening costs by an estimated 60-70% compared to traditional behavioural assays, and can be deployed in low-resource settings. Endorsements from Kent Berridge at University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU validate the theoretical foundation and methodological rigour of this work. The provisional patent filed Q3 2026 on the CCT core architecture protects the intellectual property while enabling open-source dissemination of the screening platform under Apache 2.0 licensing. This application seeks to establish a partnership with a US-based research institution to meet R01 eligibility requirements while maintaining my independent research programme. The proposed work will extend the IMPRINT platform to screen for safer analgesics and psychostimulants, targeting the opioid crisis and stimulant use disorder markets. My background as a licensed pharmacist with computational pharmacology expertise bridges the gap between clinical need and assay development. The NIH programme specifically calls for novel assay technologies that accelerate probe and drug discovery. The CCT model, with its formal mathematical specification published on OSF and Zenodo, provides exactly this capability. I request the opportunity to present the full technical validation and discuss partnership pathways with NIH programme staff. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction pharmacology: existing screening assays measure reward magnitude or dopamine release but fail to capture the conjunctive encoding process that consolidates drug-reward associations into long-term memory. My framework posits that addiction liability depends on three simultaneous conditions crossing a threshold: dopamine D1 receptor activation above 0.7 microM, NMDA receptor-mediated calcium influx exceeding 200 nM, and beta-arrestin2 recruitment at mu-opioid receptors above 40% of maximal response. Only when all three conditions are met simultaneously does the brain encode the drug-reward memory that drives compulsive use. The formal mathematical specification, published on OSF (DOI 10.17605/OSF.IO/EMY4U), models this as a three-dimensional phase space where the encoding probability is the product of sigmoidal activation functions for each pathway. The Bayesian population dynamics model, archived on Zenodo (DOI 10.5281/zenodo.20492472), incorporates inter-individual variability in receptor densities, metabolic rates, and genetic polymorphisms. Validation using ODE/RK45 numerical integration across 10,000 parameter combinations demonstrated that the model predicts encoding probability reduction from 0.855 to 0.122 when all three pathways are simultaneously antagonised, representing an 85.8% reduction. Super-additivity analysis revealed a 12.8 percentage point enhancement beyond additive predictions, confirming synergistic interactions between the three pathways. The IMPRINT platform translates this model into a practical screening assay. The pipeline accepts compound SMILES strings, computes ADMET properties using RDKit and QSAR models, predicts receptor binding affinities via AutoDock Vina and AlphaFold-generated structures, and feeds these parameters into the CCT Bayesian model to output an addiction liability score. Validation against 47 known addictive and 53 non-addictive compounds from the Drug Enforcement Administration schedule database yielded an AUROC of 0.634, with ongoing optimisation targeting 0.85 through inclusion of pharmacokinetic parameters and metabolite profiles. The TOPOLOGIX platform extends this capability by applying topological data analysis to drug-protein interaction networks. Persistent homology of bipartite simplicial complexes identifies structural features associated with hERG cardiotoxicity, enabling simultaneous screening for addiction liability and cardiac safety. The GATE platform evaluates neural-stimulation safety for BCI applications, broadening the assay portfolio. The proposed NIH-funded work will: (1) expand the validation dataset to 500 compounds with known abuse liability, (2) integrate the IMPRINT pipeline with the TOPOLOGIX cardiotoxicity module, (3) develop a web-based interface for community use, and (4) partner with a US-based pharmacology laboratory for wet-lab validation of top 20 predicted hits. The provisional patent filed Q3 2026 covers the tripartite threshold algorithm and its application to compound screening, ensuring NIH investment generates protectable intellectual property. This assay addresses the NIH programme goal of discovering chemical probes and drugs by enabling early elimination of compounds with high addiction liability, reducing the 90% failure rate in CNS drug development. The computational approach requires no animal subjects, aligns with NIH principles of rigor and reproducibility through pre-registered hypotheses and open-source code, and can be deployed globally to address the addiction burden in low- and middle-income countries. BUDGET NARRATIVE The proposed budget supports a 24-month project to validate and deploy the IMPRINT addiction liability screening assay. Personnel costs include 0.5 FTE for the Principal Investigator at $45,000 per year, reflecting independent researcher status with no institutional salary support. Equipment costs of $12,000 cover a dedicated GPU workstation for molecular dynamics simulations and Bayesian MCMC computations. Computational resources at $8,000 per year fund cloud-based HPC access through Amazon Web Services for parallel screening of compound libraries. Supplies at $5,000 cover software licenses for RDKit, PyMC, and AlphaFold updates. Travel at $4,000 supports one visit to the collaborating US institution and attendance at the Society for Neuroscience annual meeting. Publication costs at $3,000 cover open-access fees for two manuscripts. Indirect costs at 10% of direct costs total $7,700. Total direct costs $77,000, total indirect costs $7,700, total requested $84,700. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun earned a Bachelor of Pharmacy from the University of Ibadan in 2021 with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and is licensed by the Pharmacists Council of Nigeria. From 2021 to 2024, I served as a Research Assistant at the Centre for Drug Discovery, Development and Production, performing molecular docking studies of NMDA receptor antagonists and insulin analogues. Concurrently, I worked as a Bioinformatics Researcher with the Genomic Health Research Unit and the Global Surveillance of Antimicrobial Resistance project, building AMR surveillance pipelines using Nextflow and SLURM on HPC clusters. Since January 2025, I have conducted independent research on the Conjunctive Consolidation Threshold model, producing three sole-authored preprints on OSF and Zenodo. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper on alcohol pharmacology is under review at Alcohol (Elsevier). I built the IMPRINT, TOPOLOGIX, and GATE platforms, each with public GitHub repositories. I received an arXiv endorsement from Samuel Gershman at Harvard University. Professional employment includes Clinical Pharmacist at Ramset Pharmacy from January to March 2026, and National Product Manager at Synthcare since March 2026, where I oversee computational drug discovery pipelines. My computational skills encompass Python with scipy, numpy, PyMC, and pandas; R for statistical analysis; topological data analysis with Ripser and Gudhi; neural simulation with NEURON and Brian2; protein structure prediction with AlphaFold; molecular dynamics with GROMACS; docking with AutoDock; and workflow management with Nextflow and SLURM. FACILITIES AND EQUIPMENT Current computational resources include a personal workstation with 64 GB RAM and an NVIDIA RTX 4090 GPU, sufficient for molecular dynamics simulations of up to 100,000 atoms and Bayesian MCMC sampling with 10,000 iterations. Cloud computing access through Amazon Web Services provides elastic scaling for compound library screening. The TOPOLOGIX platform runs on a dedicated server with 128 GB RAM and 16 CPU cores. All software is open-source and installed locally. No wet laboratory facilities are available at the independent researcher location; wet-lab validation will be performed at the collaborating US institution. COLLABORATION LETTER A formal collaboration letter from a US-based research institution is required for R01 eligibility. The applicant has initiated discussions with the Laboratory for Computational Neuroscience at Princeton University, where Nathaniel Daw has expressed interest in hosting the IMPRINT validation studies. A signed letter of support from Dr. Daw will be provided upon conditional award notification. Alternative collaborations are being explored with the University of Michigan Addiction Research Center, where Kent Berridge has agreed to serve as a scientific advisor. CHECKLIST - [ ] Completed SF424 (R&R) application form - [ ] Project Summary/Abstract (300 words max) - [ ] Project Narrative (3 sentences) - [ ] Research Strategy (12 pages max) - [ ] Bibliography and References Cited - [ ] Biographical Sketch (5 pages max) - [ ] Budget and Budget Justification - [ ] Facilities and Other Resources - [ ] Equipment description - [ ] Collaboration letter from US-based institution - [ ] Letters of support from Kent Berridge, Samuel Gershman, Nathaniel Daw - [ ] Provisional patent documentation (Q3 2026) - [ ] Preprint DOIs: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472 - [ ] ORCID iD: 0009-0001-9272-6735 - [ ] GitHub repository links for IMPRINT, TOPOLOGIX, GATE - [ ] Proof of PCN pharmacist license - [ ] Transcript from University of Ibadan - [ ] Data management and sharing plan - [ ] Human subjects research determination (not applicable) - [ ] Vertebrate animals statement (not applicable) EDITOR NOTES - Eligibility risk: R01 requires a US-based institution as applicant. The applicant is an independent researcher in Nigeria. A formal collaboration with a US university or research institute is mandatory before submission. Verify that the collaborating institution agrees to submit as the applicant organization. - The AUROC of 0.634 for IMPRINT validation is modest. The research statement should acknowledge this and describe specific optimisation strategies to reach 0.85, including planned dataset expansion and pharmacokinetic parameter integration. - The provisional patent filing date is listed as Q3 2026, which is before the grant deadline of September 7, 2026. Confirm that the patent application has been filed or provide the actual filing date and serial number. - The budget narrative assumes 0.5 FTE for the PI at $45,000 per year. Verify that this salary level is appropriate for an independent researcher with no institutional base and that the NIH will accept this rate without a formal institutional salary scale. - The collaboration letter from Nathaniel Daw or Kent Berridge is listed as conditional upon award. NIH typically requires the letter at time of submission. Secure a signed letter before the deadline or identify an alternative US-based collaborator who can provide immediate support.